Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma

OncoImmunology

Volumn 5, Issue 2, 2016, Pages

  Vandenberk, Lien ^a   Garg, Abhishek D ^b   Verschuere, Tina ^a   Koks, Carolien ^a   Belmans, Jochen ^a   Beullens, Monique ^b   Agostinis, Patrizia ^b   De Vleeschouwer, Steven ^c   Van Gool, Stefaan W ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^c KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Antitumor immunity; dendritic cell vaccination; high grade glioma; oxidation associated molecular patterns (OAMPs); protein carbonylation; whole tumor lysate

Indexed keywords

EID: 84959386808     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1083669     Document Type: Article

References (72)

1. D.N.Louis, H.Ohgaki, O.D.Wiestler, W.K.Cavenee, P.C.Burger, A.Jouvet, B.W.Scheithauer, P.Kleihues. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114:97-109; PMID:17618441; http://dx.doi.org/10.1007/s00401-007-0243-4
2. R.Stupp, W.P.Mason, M.J.van den Bent, M.Weller, B.Fisher, M.J.Taphoorn, K.Belanger, A.A.Brandes, C.Marosi, U.Bogdahn, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330
3. C.A.Koks, A.D.Garg, M.Ehrhardt, M.Riva, L.Vandenberk, L.Boon, S.De Vleeschouwer, P.Agostinis, N.Graf, S.W.Van Gool. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer 2015; 136:E313-25; PMID:25208916; http://dx.doi.org/10.1002/ijc.29202
4. L.Galluzzi, E.Vacchelli, J.M.Bravo-San Pedro, A.Buque, L.Senovilla, E.E.Baracco, N.Bloy, F.Castoldi, J.P.Abastado, P.Agostinis, Classification of current anticancer immunotherapies. Oncotarget 2014; 5:12472-508; PMID:25537519; http://dx.doi.org/10.18632/oncotarget.2998
5. A.M.Dudek, S.Martin, A.D.Garg, P.Agostinis. Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity. Front Immunol 2014; 4:438; PMID:24376443; http://dx.doi.org/10.3389/fimmu.2013.00438
6. J.X.Cao, X.Y.Zhang, J.L.Liu, D.Li, J.L.Li, Y.S.Liu, M.Wang, B.L.Xu, H.B.Wang, Z.X.Wang. Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis. PLoS One 2014; 9:e107173; PMID:25215607; http://dx.doi.org/10.1371/journal.pone.0107173
7. A.D.Garg, S.Martin, J.Golab, P.Agostinis. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ 2014; 21:26-38; PMID:23686135; http://dx.doi.org/10.1038/cdd.2013.48
8. G.P.Dunn, A.T.Bruce, H.Ikeda, L.J.Old, R.D.Schreiber. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; PMID:12407406; http://dx.doi.org/10.1038/ni1102-991
9. K.Palucka, J.Banchereau. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; http://dx.doi.org/10.1016/j.immuni.2013.07.004
10. A.B.Heimberger, M.Abou-Ghazal, C.Reina-Ortiz, D.S.Yang, W.Sun, W.Qiao, N.Hiraoka, G.N.Fuller. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 2008; 14:5166-72; PMID:18698034; http://dx.doi.org/10.1158/1078-0432.CCR-08-0320
11. C.A.Crane, B.J.Ahn, S.J.Han, A.T.Parsa. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol 2012; 14:584-95; PMID:22406925; http://dx.doi.org/10.1093/neuonc/nos014
12. Y.Komohara, K.Ohnishi, J.Kuratsu, M.Takeya. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008; 216:15-24; PMID:18553315; http://dx.doi.org/10.1002/path.2370
13. I.F.Parney, J.S.Waldron, A.T.Parsa. Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J Neurosurg 2009; 110:572-82; PMID:19199469; http://dx.doi.org/10.3171/2008.7.JNS08475
14. S.F.Hussain, D.Yang, D.Suki, K.Aldape, E.Grimm, A.B.Heimberger. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 2006; 8:261-79; PMID:16775224; http://dx.doi.org/10.1215/15228517-2006-008
15. O.Kepp, L.Senovilla, I.Vitale, E.Vacchelli, S.Adjemian, P.Agostinis, L.Apetoh, F.Aranda, V.Barnaba, N.Bloy, Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3:e955691; PMID:25941621; http://dx.doi.org/10.4161/21624011.2014.955691
16. R.M.Prins, X.Wang, H.Soto, E.Young, D.N.Lisiero, B.Fong, R.Everson, W.H.Yong, A.Lai, G.Li, Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother 2013; 36:152-7; PMID:23377664; http://dx.doi.org/10.1097/CJI.0b013e3182811ae4
17. W.Maes, G.G.Rosas, B.Verbinnen, L.Boon, S.De Vleeschouwer, J.L.Ceuppens, S.W.Van Gool. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol 2009; 11:529-42; PMID:19336528; http://dx.doi.org/10.1215/15228517-2009-004
18. C.L.Chiang, L.E.Kandalaft, J.Tanyi, A.R.Hagemann, G.T.Motz, N.Svoronos, K.Montone, G.M.Mantia-Smaldone, L.Smith, H.L.Nisenbaum, A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 2013; 19:4801-15; PMID:23838316; http://dx.doi.org/10.1158/1078-0432.CCR-13-1185
19. H.S.Kim, Y.S.Choo, T.Koo, S.Bang, T.Y.Oh, J.Wen, S.Y.Song. Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer. Immunol Lett 2006; 103:142-8; PMID:16313973; http://dx.doi.org/10.1016/j.imlet.2005.10.021
20. P.Hatfield, A.E.Merrick, E.West, D.O'Donnell, P.Selby, R.Vile, A.A.Melcher. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J Immunother 2008; 31:620-32; PMID:18600182; http://dx.doi.org/10.1097/CJI.0b013e31818213df
21. R.S.Goldszmid, J.Idoyaga, A.I.Bravo, R.Steinman, J.Mordoh, R.Wainstok. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol 2003; 171:5940-7; PMID:14634105; http://dx.doi.org/10.4049/jimmunol.171.11.5940
22. M.Obeid, T.Panaretakis, N.Joza, R.Tufi, A.Tesniere, P.van Endert, L.Zitvogel, G.Kroemer. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007; 14:1848-50; PMID:17657249; http://dx.doi.org/10.1038/sj.cdd.4402201
23. J.M.Kaminski, E.Shinohara, J.B.Summers, K.J.Niermann, A.Morimoto, J.Brousal. The controversial abscopal effect. Cancer Treat Rev 2005; 31:159-72; PMID:15923088; http://dx.doi.org/10.1016/j.ctrv.2005.03.004
24. E.M.Kim, H.S.Yang, S.W.Kang, J.N.Ho, S.B.Lee, H.D.Um. Amplification of the gamma-irradiation-induced cell death pathway by reactive oxygen species in human U937 cells. Cell Signal 2008; 20:916-24; PMID:18262755; http://dx.doi.org/10.1016/j.cellsig.2008.01.002
25. M.E.Allison, D.T.Fearon. Enhanced immunogenicity of aldehyde-bearing antigens: a possible link between innate and adaptive immunity. Eur J Immunol 2000; 30:2881-7; PMID:11069070; http://dx.doi.org/10.1002/1521-4141(200010)30:10<2881::AID-IMMU2881>3.0.CO;2-9
26. E.Carrasco-Marin, J.E.Paz-Miguel, P.Lopez-Mato, C.Alvarez-Dominguez, F.Leyva-Cobian. Oxidation of defined antigens allows protein unfolding and increases both proteolytic processing and exposes peptide epitopes which are recognized by specific T cells. Immunology 1998; 95:314-21; PMID:9824492; http://dx.doi.org/10.1046/j.1365-2567.1998.00618.x
27. A.E.Moghaddam, K.H.Gartlan, L.Kong, Q.J.Sattentau. Reactive carbonyls are a major Th2-inducing damage-associated molecular pattern generated by oxidative stress. J Immunol 2011; 187:1626-33; PMID:21742965; http://dx.doi.org/10.4049/jimmunol.1003906
28. Y.I.Miller, S.H.Choi, P.Wiesner, L.Fang, R.Harkewicz, K.Hartvigsen, A.Boullier, A.Gonen, C.J.Diehl, X.Que, Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011; 108:235-48; PMID:21252151; http://dx.doi.org/10.1161/CIRCRESAHA.110.223875
29. X.Z.West, N.L.Malinin, A.A.Merkulova, M.Tischenko, B.A.Kerr, E.C.Borden, E.A.Podrez, R.G.Salomon, T.V.Byzova. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 2010; 467:972-6; PMID:20927103; http://dx.doi.org/10.1038/nature09421
30. T.Szatmari, K.Lumniczky, S.Desaknai, S.Trajcevski, E.J.Hidvegi, H.Hamada, G.Safrany. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 2006; 97:546-53; PMID:16734735; http://dx.doi.org/10.1111/j.1349-7006.2006.00208.x
31. S.Anguille, E.L.Smits, E.Lion, V.F.van Tendeloo, Z.N.Berneman. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014; 15:e257-67; PMID:24872109; http://dx.doi.org/10.1016/S1470-2045(13)70585-0
32. R.Yamanaka, T.Abe, N.Yajima, N.Tsuchiya, J.Homma, T.Kobayashi, M.Narita, M.Takahashi, R.Tanaka. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003; 89:1172-9; PMID:14520441; http://dx.doi.org/10.1038/sj.bjc.6601268
33. C.J.Wheeler, K.L.Black, G.Liu, H.Ying, J.S.Yu, W.Zhang, P.K.Lee. Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol 2003; 171:4927-33; PMID:14568975; http://dx.doi.org/10.4049/jimmunol.171.9.4927
34. C.J.Wheeler, A.Das, G.Liu, J.S.Yu, K.L.Black. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004; 10:5316-26; PMID:15328167; http://dx.doi.org/10.1158/1078-0432.CCR-04-0497
35. J.S.Yu, G.Liu, H.Ying, W.H.Yong, K.L.Black, C.J.Wheeler. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64:4973-9; PMID:15256471; http://dx.doi.org/10.1158/0008-5472.CAN-03-3505
36. R.Yamanaka, J.Homma, N.Yajima, N.Tsuchiya, M.Sano, T.Kobayashi, S.Yoshida, T.Abe, M.Narita, M.Takahashi, Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005; 11:4160-7; PMID:15930352; http://dx.doi.org/10.1158/1078-0432.CCR-05-0120
37. C.J.Wheeler, K.L.Black, G.Liu, M.Mazer, X.X.Zhang, S.Pepkowitz, D.Goldfinger, H.Ng, D.Irvin, J.S.Yu. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 2008; 68:5955-64; PMID:18632651; http://dx.doi.org/10.1158/0008-5472.CAN-07-5973
38. R.M.Prins, H.Soto, V.Konkankit, S.K.Odesa, A.Eskin, W.H.Yong, S.F.Nelson, L.M.Liau. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011; 17:1603-15; PMID:21135147; http://dx.doi.org/10.1158/1078-0432.CCR-10-2563
39. B.Fong, R.Jin, X.Wang, M.Safaee, D.N.Lisiero, I.Yang, G.Li, L.M.Liau, R.M.Prins. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One 2012; 7:e32614; PMID:22485134; http://dx.doi.org/10.1371/journal.pone.0032614
40. J.L.Lasky3rd, E.H.Panosyan, A.Plant, T.Davidson, W.H.Yong, R.M.Prins, L.M.Liau, T.B.Moore. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res 2013; 33:2047-56; PMID:23645755
41. S.Rutkowski, S.De Vleeschouwer, E.Kaempgen, J.E.Wolff, J.Kuhl, P.Demaerel, M.Warmuth-Metz, P.Flamen, F.Van Calenbergh, C.Plets, Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004; 91:1656-62; PMID:15477864; http://dx.doi.org/10.1038/sj.bjc.6602195
42. S.De Vleeschouwer, S.Fieuws, S.Rutkowski, F.Van Calenbergh, J.Van Loon, J.Goffin, R.Sciot, G.Wilms, P.Demaerel, M.Warmuth-Metz, Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008; 14:3098-104; PMID:18483377; http://dx.doi.org/10.1158/1078-0432.CCR-07-4875
43. H.Ardon, S.Van Gool, I.S.Lopes, W.Maes, R.Sciot, G.Wilms, P.Demaerel, P.Bijttebier, L.Claes, J.Goffin, Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol 2010; 99:261-72; PMID:20146084; http://dx.doi.org/10.1007/s11060-010-0131-y
44. H.Ardon, S.De Vleeschouwer, F.Van Calenbergh, L.Claes, C.M.Kramm, S.Rutkowski, J.E.Wolff, S.W.Van Gool. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 2010; 54:519-25; PMID:19852061; http://dx.doi.org/10.1002/pbc.22319.
45. C.E.Fadul, J.L.Fisher, T.H.Hampton, E.C.Lallana, Z.Li, J.Gui, Z.M.Szczepiorkowski, T.D.Tosteson, C.H.Rhodes, H.A.Wishart, Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 2011; 34:382-9; PMID:21499132; http://dx.doi.org/10.1097/CJI.0b013e318215e300
46. I.Elens, S.De Vleeschouwer, F.Pauwels, S.Van Gool. Resection and immunotherapy for recurrent grade Iii Glioma. Neuro-Oncology 2012; 14:61; http://dx.doi.org/10.5402/2012/530179
47. H.Ardon, S.W.Van Gool, T.Verschuere, W.Maes, S.Fieuws, R.Sciot, G.Wilms, P.Demaerel, J.Goffin, F.Van Calenbergh, Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 2012; 61:2033-44; PMID:22527250; http://dx.doi.org/10.1007/s00262-012-1261-1
48. S.De Vleeschouwer, H.Ardon, F.Van Calenbergh, R.Sciot, G.Wilms, J.van Loon, J.Goffin, S.Van Gool. Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination. Cancer Immunol Immunother 2012; 61:2105-12; PMID:22565485; http://dx.doi.org/10.1007/s00262-012-1271-z
49. R.D.Valle, A.L.de Cerio, S.Inoges, S.Tejada, F.Pastor, H.Villanueva, J.Gallego, J.Espinos, J.Aristu, M.A.Idoate, Dendritic cell vaccination in glioblastoma after fluorescence-guided resection. World J Clin Oncol 2012; 3:142-9; PMID:23293753; http://dx.doi.org/10.5306/wjco.v3.i11.142
50. T.Verschuere, J.Toelen, W.Maes, F.Poirier, L.Boon, T.Tousseyn, T.Mathivet, H.Gerhardt, V.Mathieu, R.Kiss, Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. Int J Cancer 2014; 134:873-84; PMID:23929302; http://dx.doi.org/10.1002/ijc.28426
51. D.V.Krysko, A.D.Garg, A.Kaczmarek, O.Krysko, P.Agostinis, P.Vandenabeele. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-75; PMID:23151605; http://dx.doi.org/10.1038/nrc3380
52. A.M.Dudek, A.D.Garg, D.V.Krysko, D.De Ruysscher, P.Agostinis. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 2013; 24:319-33; PMID:23391812; http://dx.doi.org/10.1016/j.cytogfr.2013.01.005
53. B.Lakshmi Narendra, K.Eshvendar Reddy, S.Shantikumar, S.Ramakrishna. Immune system: a double-edged sword in cancer. Inflamm Res: Off J Euro Histamine Res Soc [et al] 2013; 62:823-34; PMID:23868500; http://dx.doi.org/10.1007/s00011-013-0645-9
54. A.D.Garg, D.V.Krysko, P.Vandenabeele, P.Agostinis. DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown. Photochem Photobiol Sci 2011; 10:670-80; PMID:21258717; http://dx.doi.org/10.1039/c0pp00294a
55. A.D.Garg, A.M.Dudek, G.B.Ferreira, T.Verfaillie, P.Vandenabeele, D.V.Krysko, C.Mathieu, P.Agostinis. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy 2013; 9:1292-307; PMID:23800749; http://dx.doi.org/10.4161/auto.25399
56. T.Verfaillie, N.Rubio, A.D.Garg, G.Bultynck, R.Rizzuto, J.P.Decuypere, J.Piette, C.Linehan, S.Gupta, A.Samali, PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ 2012; 19:1880-91; PMID:22705852; http://dx.doi.org/10.1038/cdd.2012.74
57. T.Panaretakis, O.Kepp, U.Brockmeier, A.Tesniere, A.C.Bjorklund, D.C.Chapman, M.Durchschlag, N.Joza, G.Pierron, P.van Endert, Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28:578-90; PMID:19165151; http://dx.doi.org/10.1038/emboj.2009.1
58. A.D.Garg, D.V.Krysko, T.Verfaillie, A.Kaczmarek, G.B.Ferreira, T.Marysael, N.Rubio, M.Firczuk, C.Mathieu, A.J.Roebroek, A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31:1062-79; PMID:22252128; http://dx.doi.org/10.1038/emboj.2011.497
59. N.Nakai, G.Hartmann, S.Kishimoto, N.Katoh. Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell Melanoma Res 2010; 23:607-19; PMID:20579307; http://dx.doi.org/10.1111/j.1755-148X.2010.00736.x
60. A.Draube, N.Klein-Gonzalez, S.Mattheus, C.Brillant, M.Hellmich, A.Engert, M.von Bergwelt-Baildon. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 2011; 6:e18801; PMID:21533099; http://dx.doi.org/10.1371/journal.pone.0018801
61. M.A.Neller, J.A.Lopez, C.W.Schmidt. Antigens for cancer immunotherapy. Semin Immunol 2008; 20:286-95; PMID:18951039; http://dx.doi.org/10.1016/j.smim.2008.09.006
62. J.H.Sampson, A.B.Heimberger, G.E.Archer, K.D.Aldape, A.H.Friedman, H.S.Friedman, M.R.Gilbert, J.E.Herndon2nd, R.E.McLendon, D.A.Mitchell, Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28:4722-9; PMID:20921459; http://dx.doi.org/10.1200/JCO.2010.28.6963
63. B.J.Ahn, I.F.Pollack, H.Okada. Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel) 2013; 5:1379-412; PMID:24202450; http://dx.doi.org/10.3390/cancers5041379
64. P.E.Fecci, D.A.Mitchell, J.F.Whitesides, W.Xie, A.H.Friedman, G.E.Archer, J.E.Herndon2nd, D.D.Bigner, G.Dranoff, J.H.Sampson. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66:3294-302; PMID:16540683; http://dx.doi.org/10.1158/0008-5472.CAN-05-3773
65. B.Raychaudhuri, P.Rayman, J.Ireland, J.Ko, B.Rini, E.C.Borden, J.Garcia, M.A.Vogelbaum, J.Finke. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 2011; 13:591-9; PMID:21636707; http://dx.doi.org/10.1093/neuonc/nor042
66. A.Nishie, M.Ono, T.Shono, J.Fukushi, M.Otsubo, H.Onoue, Y.Ito, T.Inamura, K.Ikezaki, M.Fukui, Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res 1999; 5:1107-13; PMID:10353745
67. H.Zhai, F.L.Heppner, S.E.Tsirka. Microglia/macrophages promote glioma progression. Glia 2011; 59:472-85; PMID:21264953; http://dx.doi.org/10.1002/glia.21117
68. E.J.Sayour, P.McLendon, R.McLendon, G.De Leon, R.Reynolds, J.Kresak, J.H.Sampson, D.A.Mitchell. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother 2015; 64:419-27; PMID:25555571; http://dx.doi.org/10.1007/s00262-014-1651-7
69. C.L.Hawkins, P.E.Morgan, M.J.Davies. Quantification of protein modification by oxidants. Free Radical Biol Med 2009; 46:965-88; PMID:19439229; http://dx.doi.org/10.1016/j.freeradbiomed.2009.01.007
70. K.S.Fritz, D.R.Petersen. Exploring the biology of lipid peroxidation-derived protein carbonylation. Chem Res Toxicol 2011; 24:1411-9; PMID:21812433; http://dx.doi.org/10.1021/tx200169n
71. M.M.van Beers, M.Sauerborn, F.Gilli, V.Brinks, H.Schellekens, W.Jiskoot. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res 2011; 28:2393-402; PMID:21544687; http://dx.doi.org/10.1007/s11095-011-0451-4
72. A.D.Garg, P.Agostinis. ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses. Photochem Photobiol Sci: Off J Euro Photochem Assoc Eur Soc Photobiol 2014; 13:474-87; PMID:24493131; http://dx.doi.org/10.1039/c3pp50333j